Patient information letter relating to Co-vax Covid-19 research study, 2021

Patient information documents related to the Co-vax Covid-19 research study (CML-CO-VAX - Seroprotection against SARS-CoV-2 in Chronic Myeloid Leukaemia (CML) patients receiving TKI therapy), inviting CML patient Doreen Eggleton to participate, issued by Imperial College Healthcare NHS Trust, 30th July 2022. Includes schedule for vaccination and assessment tests.

Patients receiving treatment for cancer were considered a high priority for vaccination against the SARS-CoV-2 virus during the pandemic, as many had a compromised immune system. More information was needed to show the safety and efficacy of the vaccine in specific cancer patient groups. This letter invited patient Doreen Eggleton, who was diagnosed with Chronic Myeloid Leukaemia (CML) in 1998, to participate in a study of the safety and efficacy of the SARS-Cov-2 vaccine in patients with CML receiving treatment with drugs called TKI's (Tyrosine Kinase Inhibitors such as the taregted therapy Glivec). This trial used blood tests to monitor patients and their antibody response to the covid vaccines. Doreen received her 4th SARS-Cov-2 vaccine on 6th January 2022.